Spanish company Hipra says it could adapt its vaccine PHH-1V to a new variant B.1.1.529 within four months
The Spanish company expects to receive approval for its drug in the first quarter of 2022.
Hipra, the Spanish company developing a vaccine against the coronavirus, believes it would be able to adapt the drug to a variant such as the omicron, whose spread has pushed the European Union and the United States to close their borders with southern Africa on Friday.
This was stated Friday by the company’s president, David Nogareda, who explained that his proposal works on the basis of two dimers of existing coronavirus variants, so it would be possible to change one of these dimers for another that would have effects against another variant, such as the omicron. The developers of the Spanish recombinant protein covid vaccine plan to receive authorisation in the first quarter of 2022.
Nogareda has thus underlined “one of the advantages” of the vaccine he is developing and pointed out that the solution “is still not a miracle, but it is a good tool” to combat the spread of the coronavirus and all its new variants.
The Spanish vaccine, PHH-1V, has just passed phase II clinical trials and could start phase III in 2022. The aim is for the European Medicines Agency to approve it in the first quarter so that it can be manufactured from that time onwards. Nogareda assured that the company is capable of producing 600 million doses next year, an amount that could double by 2023.
The president of Hipra took part in the 16th Economic Meeting in S’Agaró (Girona), where he outlined the evolution of the company and highlighted its expertise in the treatment of coronaviruses, although until now only in animal medicine.
SOURCE EL PAIS.COM — read more in Spanish here